中文
Earlier issues
Announcement
More
Progress in Chemistry 2007, Vol. 19 Issue (05): 762-768 Previous Articles   Next Articles

• Review •

Cyclic Peptide Histone Deacetylases Inhibitors

Li Xiaohui1**; Li Jianxun1; Li Shirong1;Xiu Zhilong1;Nishino Norikazu2   

  1. 1.School of Environmental and Biological Science and Technology , Dalian University of Technology ,Dalian 116024, China;

    2.Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, Kyushu 808-0196,Japan

  • Received: Revised: Online: Published:
PDF ( 1805 ) Cited
Export

EndNote

Ris

BibTeX

Histones acetyltransferases (HAT) and histone deacetylases (HDACs) as the corresponding enzymes regulate the change of histones in two antagonist forms, acetylated or deacetylated. In recent years, inhibition of HDACs has emerged as a potential strategy in human cancer therapy, since these enzymes play a fundamental role in regulating gene expression and chromatin assembly. The histone deacetylases inhibitors (HDACIs) are potent inducers of growth arrest, differentiation and apoptosis of tumor cells, and have entered clinical trials for both solid and liquid tumors. However, the molecular basis for their anticancer selectivity remains largely unknown. An improved understanding of the structure and action mechanism of HDAC inhibitors will likely accelerate the clinical development and broaden the future scope and utility ofHDAC inhibitors will likely accelerate the clinical development and broaden the future scope and utility of HDAC inhibitors for cancer treatment. In this review, we summarize recent advances of the HDACs inhibitors of cyclic peptide in structure, mechanism of action, clinical development.
Key words: histone acetylases, histone deacetylases, histone deacetylases inhibitors, cyclic peptides

CLC Number: 

[ 1 ] Luger K, Mader A W, Richmond R K, et al . Nature , 1997 , 389(6648) : 251 —260
[ 2 ] Pennisi E. Science , 1997 , 275 (5297) : 155 —157
[ 3 ] Pazin M J , Kadonaga J T. Cell , 1997 , 89 , (3) : 325 —328
[ 4 ] Kouzarides T. Curr. Opin. , Genet . Dev. , 1999 , 9(1) : 40 —48
[ 5 ] Kr?mer O H , Gê ttlicher M, Heinzel T. Trends Endocrinol .Metab. , 2001 , 12(7) : 294 —300
[ 6 ] Nervi C , Borello U , Fazi F , et al . Cancer Res. , 2001 , 61(4) :1247 —1249
[ 7 ] Kwon H J , Kim M S , Kim M J , et al . Int . J . Cancer , 2002 , 97(3) : 290 —296
[ 8 ] Deroanne C F , Bonjean K, Servotte S , et al . Oncogene , 2002 ,21 (3) : 427 —436
[ 9 ] Yoshida M, Ma tsuyama A , Komatsu Y, et al . Current Medicinal Chemistry , 2003 , 10 : 1241 —1253
[10] Finnin M S , Donigian J R , Cohen A , et al . Nature , 1999 , 401(6749) : 188 —193
[11] Park HJ YJ , Kim Y K, Han J W, et al . MEDI2120 in Abstracts of Papers. 224th National Meeting of the American Chemical Society , Boston. 2002
[12] Marks P A , Miller T , Richon V M. Curr. Opin. Pharmacol . ,2003 , 3(4) : 344 —351
[13] Meinke P T , Liberator P. Curr. Med. Chem. , 2001 , 8 ( 2) :211 —235
[14] Kijima M, Yoshida M, Sugita K, et al . Biol . Chem. , 1993 , 268(30) : 22429 —22435
[15] Ciuffetti L M, Pope M R , Dunkle L D , et al . Biochemistry ,1983 , 22(14) : 3507 —3510
[16] Furumai R , Komatsu Y, Nishino N , et al . Proc. Natl . Acad.Sci . USA , 2001 , 98(1) : 87 —92
[17] Taunton J , Collins J L , Schreiber S L. J . Am. Chem. Soc. ,1996 , 118 (43) : 10412 —10422
[18] Nishino N , Jose B , Shinta R , et al . Bioorg. Med. Chem. ,2004 , 12(22) : 5777 —5784
[19] Mohammed P I , Kato T , Okauchi T , et al . Bioorg. Med.Chem. , 2006 , 14(10) : 3438 —3446
[20] Komatsu Y, Tomizaki K, Tsukamoto M, et al . Cancer Res. ,2001 , 61 (11) : 4459 —4466
[21] Binoy J , Yusuke O , Tamaki K, et al . Bioorg. Med. Chem.Lett . , 2004 , 14(21) : 5343 —5346
[22] Darkin-Rattray S J , Gurnett A M, Myers R W, et al . Proc. Natl .Acad. Sci . USA , 1996 , 93(23) : 13143 —13147
[23] Singh S B , Zink D L , Liesch J M, et al . Org. Lett . , 2001 , 3(18) : 2815 —2818
[24] Shin B S , Chang H S , Park E H , et al . Biopharm. Drug Dispos. , 2006 , 27(2) : 69 —75
[25] Han J W, Ahn S H , Park S H , et al . Cancer Res. , 2000 , 60(21) : 6068 —6074
[26] Kwon S H , Ahn S H , Kim Y K, et al . J . Biol . Chem. , 2002 ,277(3) : 2073 —2080
[27] Singh S B , Zink D L , Liesch J M, et al . J . Org. Chem. , 2002 ,67(3) : 815 —825
[28] Meinke P T , Colletti S L , Ayer M B , et al . Tetrahedron Letters ,2000 , 41(41) : 7831 —7835
[29] Colletti S L , Myers R W, Darkin-Rattray S J , et al . Bioorg.Med. Chem. Lett . , 2001 , 11(2) : 107 —111
[30] Colletti S L , Myers R W, Darkin-Rattray S J , et al . Bioorg.Med. Chem. Lett . , 2001 , 11(2) : 113 —117
[31] Collettic S L , Myers R W, Darkin-Rattay S J , et al . Tetrahedron Lett . , 2004 , 41 : 7837 —7841
[32] Nishino N , Yoshikawa D , Wawanabe L A , et al . Bioorg. Med.Chem. Lett . , 2004 , 14(10) : 2427 —2431
[33] Mori H , Abe F , Furukawa S , et al . J . Antibiot . ( Tokyo ) ,2003 , 56(2) : 72 —79 ; 80 —86
[34] Xie W Q , Zou B , Pei D Q , et al . Org. Lett . , 2005 , 7 (13) :2775 —2777
[35] Rodriquez M, Terracciano S , Cini E , et al . Angew. Chem. Int .Ed. , 2006 , 45(3) : 423 —427
[36] Ueda H , Nakajima H , Hori Y, et al . J . Antibio. 1994 , 47 :301 —310
[37] Shigematsu N , Ueda H , Takase S , et al . J . Antibiot . , 1994 ,47 : 311 —314
[38] Furumai R , Matsuyama A , Kobashi , et al . Cancer Res. , 2002 ,62 : 4916 —4921
[39] Li KW, Wu J , Xing W, et al . J . Am. Chem. Soc. , 1996 , 118(30) : 7237 —7238
[40] Piekarz R L , Robey R , Sandor V , et al . Blood , 2001 , 98 (9) :2865 —2868
[41] Sawa H , Murakami H , Kumagai M, et al . Acta Neuropathol . ,2004 , 107 (6) : 523 —531
[42] Taura K, Yamamoto Y, Nakajima A , et al . J . Gene Med. ,2004 , 6(5) : 526 —536
[43] Shizukuda Y, Piekarz R L , Bates S E , et al . Cardiovascular Drugs and Therapy , 2005 , 19(1) : 89 —90
[44] Nishino N , Jose B , Okamura S , et al . Org. Lett . , 2003 , 5(26) : 5079 —5082
[45] Jose B , Okamura S , Kato T , et al . Bioorg. Med. Chem. , 2004 ,12(6) : 1351 —1356
[46] Mai A , Massa S , Pezzi R , et al . J . Med. Chem. , 2005 , 48(9) :3344 —3353
[47] Furumai R , Matsuyama A , Kobashi N , et al . Cancer Res. ,2002 , 62 : 4916 —4921
[48] Hu E , Dul E , Sung C M, et al . J . Pharmacol . Exp. Ther. ,2003 , 307 : 720 —728
[49] Glaser K B , Li J , Pease L , et al . Biochem. Biophys. Res.Commun. , 2004 , 325 (3) : 683 —690
[50] Jessica E B , Melissa J P , Ricky W J . Nature Reviews Drug Discovery , 2006 , 5 : 769 —784
[51] Cote S , Rosenauer A , Bianchini A , et al . Blood , 2002 , 100 :2586 —2596
[52] Cameron E E , Bachman K E , Myohanen S , et al . Nature Genet . , 1999 , 21 : 103 —107
[53] Rosato R R , Almenara J A , Yu C R , Grant S. Mol . Pharmacol . ,2004 , 65 : 571 —581
[54] Drummond D C , Noble C O , Kirpotin D B , et al . Annu. Rev.Pharmacol . Toxicol . , 2005 , 45 : 495 —528
[55] Pauer L R , Olivares J , Cunningham C , et al . Cancer Invest ,2004 , 22 : 886 —896
[56] Kitazono M, Bates S , Fok P , et al . Cancer Biol . Ther. , 2002 ,1 : 665 —668
[57] Fuino L , Bali P , Wittmann S , et al . Mol . Cancer Ther. , 2003 ,2 : 971 —984
[58] Bhalla KN. J . Clin. Oncol . , 2005 , 23 : 3971 —3993
[1] Liang Yanyu, Tang Shan, Zheng Jishen. Cell-Permeable Cyclic Peptides [J]. Progress in Chemistry, 2014, 26(11): 1793-1800.
[2] Li Xiaohui*, Huang Meiling, Liu Lina, Wang Yanyun. Cyclopeptide Histone Deacetylase Inhibitors [J]. Progress in Chemistry, 2014, 26(09): 1527-1536.
[3] Wu Zhenyu,Zhang Yunhong,Wang Hui,Ma Fengqi. Research on Design and Synthesis of Cyclic Peptides [J]. Progress in Chemistry, 2002, 14(02): 113-.